Objectives: to investigate differences in amenable mortality among Italian Regions using the lists of causes of death conceived by Nolte and McKee, and Tobias and Yeh, and assess whether these differences are in part attributable to the list used. We also estimated the contribution of amenable mortality to the gaps in all-cause mortality among North, Centre and South of Italy.
Design: cross-sectional study. SETTING AND PARTICIPANTS: Italian National Institute of Statistics (ISTAT) mortality data for the period 2006-2009.
Main Outcome Measures: age- and gender-standardised amenable mortality rates.
Results: for the period 2006-2009, in Italy the Nolte and McKee mortality rate was 62.38 per 100,000 inhabitants, ranging from 54.92 in the Autonomous Province of Bolzano (Northern Italy) to 62.38 in Campania Region (Southern Italy). For the same period, the Tobias and Yeh mortality rate was 69.59 per 100,000, ranging from 60.06 in Marche Region (Central Italy) to 88.12 in Campania Region. Using Nolte and McKee's list, amenable mortality accounted for 40.65% of the differences in all-cause mortality between Northern and Southern Italy, and for 33.66% of the differences between Southern and Central Italy. Using Tobias and Yeh's list, amenable mortality accounted for 53.99% of the differences in all-cause mortality between Northern and Southern Italy, and for 42.62% of the differences between Southern and Central Italy.
Conclusion: the findings here presented show that amenable mortality rates calculated using Tobias and Yeh's list were higher than rates calculated using Nolte and McKee's list. Geographical pattern of amenable mortality derived by the two lists were almost coincident. Moreover, amenable mortality makes a substantial contribution to inequalities in health among North, Centre and South of Italy.
Download full-text PDF |
Source |
---|
Pharmaceutics
December 2024
Division of Pulmonology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan 50612, Republic of Korea.
Lung cancer remains a major global health problem because of its high cancer-related mortality rate despite advances in therapeutic approaches. Non-small cell lung cancer (NSCLC), a major subtype of lung cancer, is more amenable to surgical intervention in its early stages. However, the prognosis for advanced NSCLC remains poor, owing to limited treatment options.
View Article and Find Full Text PDFLancet
January 2025
Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain. Electronic address:
Int J Surg
December 2024
Hepatobiliary Surgery Department, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
J Inherit Metab Dis
January 2025
Department of Pediatrics, Emma Children's Hospital, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.
Inborn errors of metabolism (IEMs) are rare genetic conditions with significant morbidity and mortality. Technological advances have increased therapeutic options, making it challenging to remain up to date. A centralized therapy knowledgebase is needed for early diagnosis and targeted treatment.
View Article and Find Full Text PDFNephrology (Carlton)
January 2025
Division of Nephrology, School of Clinical Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong SAR.
Prevention of end-stage kidney disease (ESKD) is a major objective in the management of patients with lupus nephritis (LN). Chronic kidney disease (CKD) of variable severity is common in these patients, but recent literature has mostly focused on novel immunosuppressive treatments for acute LN, while the data on CKD is relatively limited. This scoping review aims to summarise available data on the prevalence and risk factors for CKD in patients with LN.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!